Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
1.540
+0.120 (8.45%)
May 5, 2025, 11:10 AM EDT - Market open
Traws Pharma Revenue
In the year 2024, Traws Pharma had annual revenue of $226.00K. Traws Pharma had revenue of $56.00K in the quarter ending December 31, 2024.
Revenue (ttm)
$226.00K
Revenue Growth
n/a
P/S Ratio
9.76
Revenue / Employee
$32,286
Employees
7
Market Cap
7.81M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Thermo Fisher Scientific | 42.90B |
TRAW News
- 4 weeks ago - Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript - Seeking Alpha
- 5 weeks ago - Traws Pharma Announces Management Updates - GlobeNewsWire
- 5 weeks ago - Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET - GlobeNewsWire
- 5 weeks ago - Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR - GlobeNewsWire
- 6 weeks ago - Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR - GlobeNewsWire
- 2 months ago - Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil - GlobeNewsWire
- 2 months ago - Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule - GlobeNewsWire
- 3 months ago - Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu - PRNewsWire